Current status of interleukin-6 inhibitors

Drugs of the Future

Volumn 22, Issue 4, 1997, Pages 391-395

  Barton, Beverly E ^a   Tagat, Jayaram R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 CHLOROPHENYL) 4,5 DIPHENYL 2 IMIDAZOLINE; ANTIINFLAMMATORY AGENT; ERYLUSAMINE B; GROWTH FACTOR; HYBRID PROTEIN; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; INHIBITOR PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; PIROXICAM; PLANT EXTRACT; RETINOIC ACID; SCH 21418; SCH 24471; SUPLATAST TOSYLATE; SURAMIN; TENIDAP; TOXIN; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ANTIINFLAMMATORY ACTIVITY; CACHEXIA; CLINICAL TRIAL; CONJUGATE; HEART MYXOMA; HUMAN; IMMUNOMODULATION; KAPOSI SARCOMA; MULTIPLE MYELOMA; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

EID: 0030745017     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Aderka, D., Le, J., Vilcek, J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989, 143: 3517-23.
2. Aderka, D., Maor, Y., Novick, D. et al. Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-α. Blood 1993, 81: 2076-84.
3. Barton, B.E. Effect of interleukin-6 in septic shock. Drug News Perspect 1993, 6: 641-6.
4. Barton, B.E., Finkelman, F.D. Anti-inflammatory cytokines. Agents Actions 1993, 39: R1-3.
5. Barton, B.E., Jackson, J.V. The protective role of IL-6 in a septic shock model. Infect Immun 1993, 61: 1496-9.
6. Barton, B.E., Shortall, J., Jackson, J.V. Interleukins 6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model. Infect Immun 1996, 64: 714-8.
7. Barton, B.E. The biological effects of interleukin 6. Med Res Rev 1996, 16: 87-109.
8. Taga, T., Hibi, M., Hirata, Y. et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989, 58: 573-81.
9. Davis, S., Aldrich, T.H., Stahl, N. et al. LIFRβ and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science 1993, 260: 1805-8.
10. Gearing, D.P., Bruce, A.G. Oncostatin M binds the high-affinity leukemia inhibitory factor receptor. New Biol 1992, 4: 61-5.
11. Gearing, D.P., Comeau, M.R., Friend, D.J. et al. The IL-6 signal transducer, gp130: An oncostatin M receptor and affinity converter for the LIF receptor. Science 1992, 255: 1434-7.
12. Hilton, D.J., Hilton, A.A., Raicevic, A. et al. Cloning of a murine IL-11 receptorα-chain: Requirement for gp130 for high affinity binding and signal transduction. EMBO J 1994, 13: 4765-75.
13. Yin, T., Taga, T., Tsang, M.L.-S., Yasukawa, K., Kishimoto, T., Yang, Y.-C. Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction. J Immunol 151: 2555-61.
14. Chen, L., Novick, D., Rubinstein, M., Revel, M. Recombinant interferon-β2 (interleukin-6) induces myeloid differentiation. FEBS Lett 1988, 239.
15. 3 in induction of myeloid differentiation of human leukemic cell lines. J Leuk Biol 1992, 51: 237-43.
16. Galandrini, R., Cernetti, C., Albi, N. et al. Interleukin-6 is constitutively produced by human CTL clones and is required to maintain their cytolytic function. Cell Immunol 1991, 138: 11-23.
17. Hudak, S., Thompson-Snipes, L., Rocco, C., Jackson, J., Pearce, M., Rennick, D. Anti-IL-6 antibodies suppress myeloid cell production and the generation of CFU-c in long term bone marrow cultures. Exp Hematol 1992, 20: 412-7.
18. Jansen, J.H., Kluin-Nelemans, J.C., Van Damme, J., Wientjens, J.H.M., Willemze, R., Fibbe, W.E. Interleukin 6 is a permissive factor for monocytic colony formation by human hematopoietic progenitor cells. Exp Med 1992, 175: 1151-4.
19. Ming, J., Cernetti, C., Steinman, R.M., Granelli-Piperno, A. Interleukin-6 is the principal cytolytic T lymphocyte differentiation factor for thymocytes in human leukocyte conditioned medium. J Mol Cell Immunol 1989, 4: 203-12.
20. Okada, M., Kitahara, M., Kishimoto, S., Matsuda, T., Hirano, T., Kishimoto, T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988, 141: 1543-9.
21. Takai, Y., Wong, G.G., Clark, S.C., Burakoff, S.J., Herrmann, S.H. B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J Immunol 1988, 140: 508-12.
22. Ulich, T.R., del Castillo, J., Guo, K. In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating number of RBCs and WBCs. Blood 1989, 73: 108-10.
23. Dalrymple, S.A., Lucian, L.A., Slattery, R. et al. IL-6 deficient mice are highly susceptible to L. monocytogenes infection: Correlation with inefficient neutrophilia. Infect Immun 1995, 63: 2262-8.
24. Hirano, T., Matsuda, T., Turner, M. et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunology 1988, 18: 1797-801.
25. Houssiau, F.A., Devogelaer, J.-P., Van Damme, J., Nagant de Deuxchaisnes, C., Van Snick, J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthrides. Arthritis Rheum 1988, 31: 784-8.
26. Vandenabeele, P., Abramowicz, D., Berus, D. et al. Increased IL-6 production and IL-6 mediates Ig secretion in murine host-vs-graft disease. J Immunol 1993, 150: 4179-87.
27. Al-Humidan, A., Ralston, S.H., Hughes, D.E. et al. Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae. J Bone Miner Res 1991, 6: 3-8.
28. Barton, B.E., Mayer, R. IL-3 and IL-6 do not induce bone resorption in vitro. Cytokine 1990, 2: 217-20.
29. Kurihara, N., Bertolini, D., Suda, T., Akiyama, Y., Roodman, G.D. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human bone marrow cultures by inducing IL-1 release. J Immunol 1990, 144: 4226-30.
30. Roodman, G.D. Perspectives. Interleukin-6: An osteotropic factor? J Bone Miner Res 1992, 7: 475-8.
31. Roodman, G.D., Kurihara, N., Ohsaki, Y. et al. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest 1992, 89: 46-52.
32. Hilbert, D.M., Kopf, M., Mock, B.A., Kohler, G., Rudikoff, S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med 1995, 182: 243-8.
33. Hirano, T., Taga, T., Yasukawa, K. et al. Human B cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci USA 1987, 84: 228-31.
34. Jourdan, M., Bataille, R., Seguin, J., Zhang, X.-G., Chaptal, R.A., Klein, B. Constitutive production of interleukin-6 and immunologic features in cardiac myxoma. Arthritis Rheum 1990, 33: 398-402.
35. Klein, B., Zhang, X.-G., Jourdan, J. et al. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw 1990, 1: 193-201.
36. Miles, S.A., Rezai, A.R., Salazar-Gonzalez, J.F. et al. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 1990, 87: 4068-72.
37. Nair, B.C., DeVico, A.L., Nakamura, S. et al. Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M. Science 1992, 255: 1430-2.
38. Zhang, X.G., Klein, B., Bataille, R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989, 74: 11-3.
39. Grigorieva, I., Woodliff, J., MacLeod, S.L., Hardin, J., Epstein, J. Interleukin-6 negates the cytotoxicity of dexamethasone in myeloma. Proc Annu Meet Am Assoc Cancer Res 1995, 1995.
40. Hardin, J., MacLeod, S., Grigorieva, I., Chang, R., Xiao, H., Epstein, J. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994, 84: 3063-70.
41. Oldenburg, H.S.A., Rogy, M.A., Lazarus, D.D. et al. Cachexia and the acute-phase response in inflammation are regulated by interleukin-6. Eur J Immunol 1993, 23: 1889-94.
42. Strassman, G., Masui, Y., Chizzonite, R., Fong, M. Mechanisms of cancer cachexia. J Immunol 1993, 150: 2341-5.
43. Matsuda, T., Hirano, T., Kishimoto, T. Establishment of an interleukin 6 (IL-6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL-6 monoclonal antibodies. Eur J Immunol 1988, 18: 951-6.
44. Shimamura, T., Taki, S., Honda, H., Yokota, M., Ito, S., Takahara, Y. Analysis of interleukin 6 (IL-6)/IL-6 receptor system using monoclonal anti-IL-6 antibodies. Mol Immunol 1991, 28: 1155-61.
45. Klein, B., Wijdenes, J., Zhang, X.-G. et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991, 78: 1198-204.
46. Sato, K., Tsuchiya, M., Saldanha, J. et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 1993, 53: 851-6.
47. Fitzgerald, D., Pastan, I. Recombinant Pseudomonas exotoxins of low animal toxicity and high cytocidal activity. US 90522182.
48. Pastan, I. Cloning of chimeric gene encoding interleukin 6 and a portion of Pseudomonas exotoxin. US 88278601.
49. Siegall, C.B., Chaudary, V.K., FitzGerald, D.J., Pastan, I. Cytotoxic activity of an interleukin 6-Pseudomonas exotoxin fusion protein on human myeloma cells. Proc Natl Acad Sci USA 1988, 85: 9738-42.
50. Siegall, C.B., FitzGerald, D.J., Pastan, I. Cytotoxicity of IL-6-PE40 and derivatives on tumor cells expressing a range of interleukin 6 receptor levels. J Biol Chem 1990, 265: 16318-23.
51. Chadwick, D.E., Jean, L.F., Jamal, N., Messner, H.A., Murphy, J.R., Minden, M.D. Differential sensitivity of human myeloma cell lines and normal bone marrow colony forming cells to a recombinant diphtheria toxin-interleukin 6 fusion protein. Br J Haematol 1993, 85: 25-36.
52. May, L.T., Neta, R., Moldawer, L.L., Kenney, J.S., Patel, K., Sehgal, P.B. Antibodies chaperone circulating IL-6. J Immunol 1993, 151: 3225-36.
53. Novick, D., Engelmann, H., Revel, M., Leitner, O., Rubinstein, M. Monoclonal antibodies to the soluble human IL-6 receptor: Affinity purification, ELISA, and inhibition of ligand binding. Hybridoma 1991, 10: 137-46.
54. Huang, Y.-W., Vitetta, E.S. A monoclonal anti-human IL-6 receptor antibody inhibits the proliferation of human myeloma cells. Hybridoma 1993, 12: 621-30.
55. Suzuki, H., Yasukawa, K., Saito, T. et al. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. Eur J Immunol 1992, 22 1989-93.
56. Brakenhoff, J.P.J., De Horn, F.D., Fontaine, V. et al. Development of a human interleukin-6 receptor antagonist. J Biol Chem 1994, 269: 86-93.
57. de Horn, F., Ehlers, M., Rose John, S. et al. Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells. J Exp Med 1994, 180: 2395-400.
58. Ekida, T., Nishimura, C., Masuda, S., Itoh, S., Shimada, I., Arata, Y. A receptor-binding peptide from human interleukin-6: Isolation and a proton nuclear magnetic resonance study. Biochem Biophys Res Commun 1992, 189: 211-20.
59. Toy, J. (Tosoh Corp.). Interleukin-6 partial peptide comprises specified amino acid sequence for treating auto-immune disease. JP 05097892.
60. Ciliberto, G., Tonniatti, C. Interleukin-6 antagonists comprising soluble form of IL-6 receptor containing mutation in interface binding with gp130, for prevention and treatment of inflammatory, autoimmune, and neoplastic diseases. WO 9617869.
61. Castell, J.V., Andus, T., Kunz, D., Heinrich, P.C. Interleukin-6. The major regulator of acute-phase protein synthesis in man and rat. Ann NY Acad Sci 1989, 557: 87.
62. Sipe, J.D., Bartle, L.M., Loose, L.D. Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen. J Immunol 1992, 148: 480-4.
63. Blackburn, W.D., Prupas, H.M., Silverfield, J.C. et al. Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with piroxicam-plus-hydroxychloroquine and piroxicam alone. Arthritis Rheum 1995, 38: 1447-56.
64. Wylie, G., Appelboom, T., Bolten, W. et al. A comparative study of tenidap a cytokine-modulating anti-rheumatic drug, and diclofenac in rheumatoid arthritis: A 24-week analysis of a 1-year clinical trial. Br J Rheumatol 1995, 34: 554-63.
65. Baumann, H., Strassmann, G. Suramin inhibits the stimulation of acute phase protein genes by IL-6-type cytokines in rat hepatoma cells. J Immunol 1993, 151: 1456-62.
66. Strassman, G., Fong, M., Windsor, S., Neta, R. The role of interleukin-6 in lipopolysaccharide-induced weight loss, hypoglycemia and fibrinogen production, in vivo. Cytokine 1993, 5: 285-90.
67. Walther, M.M. Suramin and its active analogs for treatment of hypercalcemia. US 500913A0.
68. Yanagihara, Y., Konawa, M., Shida, T., Koda, A. Suppression of human IgE synthesis by a new anti-allergic drug, IPD-115T.Eur J Pharmacol 1990, 183: 5.
69. Vercelli, D., Jabara, H.H., Arai, K., Yokota, Y., Geha, R. Endogenous interleukin-6 plays an obligator role in interleukin-4 dependent human IgE synthesis. Eur J Immunol 1989, 19: 1419-24.
70. Willheim, M., Gessl, A., Berger, R. et al. IL-6 augments Fc IgE receptor (FceRII)/CD23) expression on human monoblastic/monocytic cell lines U937, THP-1, and mono-MAC-6 but not on blood monocytes. J Immunol 1991, 147: 1837-42.
71. Kohda, A. A review of anti-allergic agents: An agent which inhibits the production of IgE antibody. Jpn J Allergol 1989, 38: 686-700.
72. Tagat, J.R., Nazareno, D.V., McCombie, S.W., Barton, B.E., Shortall, J., Jackson, J. Synthetic inhibitors of interleukin-6. I: 2,3,7,8-Tetrahydro-4-aryl-1H-cyclopent[e]imidazo[1,2-a]-pyridin-5(6H)-one and related compounds. Bioorg Med Chem Lett 1995, 5: 2139-42.
73. Tagat, J.R., McCombie, S.W., Barton, B.E., Jackson, J., Shortall, J. Synthetic inhibitors of interleukin-6, II: 3,5-Diaryl pyridines and meta-terphenyls. Bioorg Med Chem Lett 1995, 5: 2143-6.
74. Sugita, T., Ueno, M., Furukawa, O., Murakami, T., Takata, I., Tosa, T. Effect of a novel anti-rheumatic drug, TA-383, on type II collagen-induced arthritis - Suppressive effect of TA-383 on interleukin 6 production. Int J Pharmacol 1993, 15: 515-9.
75. Pyun, K.H., Choi, I., Kang, H.S., Lee, J.J., Kim, Y.H. Extracts of Stephania tetrandra for inhibition of interleukin-6 production. WO 9533473.
76. Fusetani, N., Sata, N., Asai, N., Matsunana, S. Isolation and structure elucidation of erylusamine B, a new class of marine natural products, which blocked an IL-6 receptor, from the marine sponge Erylus placenta Thiele. Tetrahedron Lett 1993, 34: 4067-70.
77. Hirano, T. (Tosoh Corp.). Interleukin-6 suppressors for treatment of autoimmune diseases. JP 05124957.
78. Sidell, N., Taga, T., Hirano, T., Kishimoto, T., Saxon, A. Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. J Immunol 1991, 146: 3809-14.
79. Oritani, K., Kaisho, T., Nakajima, K., Hirano, T. Retinoic acid inhibits interleukin-6-induced macrophage differentiation and apoptosis in a murine hematopoietic cell line, Y6. Blood 1992, 80: 2298-305.